相关临床试验
282
52 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
41
14.5%
已完成
125
44.3%
Enrolling By Invitation
7
2.5%
No Longer Available
1
0.3%
尚未招募
4
1.4%
招募中
19
6.7%
暂停
3
1.1%
终止
52
18.4%
Unknown
6
2.1%
撤回
24
8.5%
暂无批准数据
- PatientIQ secured $30 million in Series C funding led by Hughes & Company, with participation from existing investors Health Enterprise Partners and August Capital. - The company has grown from 200 to more than 870 healthcare organizations and captured over 70 million patient outcomes since its 2022 Series B. - The capital will expand real-world evidence capabilities for life sciences, deepen EHR integrations, and build a direct-to-patient marketplace. - PatientIQ's platform now serves more than 20 medical specialties and integrates with over 50 EHR systems, including Epic, Oracle Health and athenahealth.
- NeuroOne received ISO 13485 certification, enabling international commercialization of its OneRF Brain and Trigeminal Neuralgia Ablation Systems and Evo diagnostic lines. - Third-quarter fiscal 2026 product revenue reached $2.0 million, up 16% year over year, with product orders of $2.7 million, up 43%. - The Journal of Neurosurgery published a Mayo Clinic Jacksonville study showing OneRF procedures may be performed without interfering with implanted neuromodulation hardware. - NeuroOne's robotic-assisted StereoCED intracranial drug delivery platform is expected to be ready for investigational human clinical studies by the end of September.
- The global 3D printing medical devices market is projected to grow from USD 3.71 billion in 2025 to USD 18.61 billion by 2035, at a CAGR of 17.49%. - Key drivers include rising demand for patient-specific implants and prosthetics, increased use of surgical guides and anatomical models, and advances in biocompatible materials. - Major players such as Stratasys, 3D Systems, and Materialise are launching new multi-material and workflow automation technologies to expand clinical applications. - Technologies including selective laser sintering, bioprinting, and AI-powered design software are enabling better patient outcomes at reduced costs and faster treatment times.
- An Indiana University-led coalition has been selected for the NSF Regional Innovation Engines program, receiving $15 million over two years with potential for up to $160 million in sustained federal funding. - The NSF IMPACT Engine in Indiana aims to speed life-changing musculoskeletal innovations to market by connecting orthopedic industry leaders, top universities, and health data resources. - Nearly half of all Americans suffer from a chronic musculoskeletal disorder, underscoring the significant clinical need the initiative addresses. - The coalition aspires to train over 1,900 workers, launch more than 85 startups, bring at least 30 innovations to market, and deliver over $535 million in economic impact.
- LEM Surgical's Dynamis robot becomes the first multi-arm system for hard tissue surgery to receive FDA 510(k) clearance, featuring two surgical guidance arms and one optical navigation arm. - Monogram Technologies earned FDA clearance for its mB´s robot designed for total knee replacement, with plans for expansion into additional orthopedic applications. - Southern Hills Hospital performed the world's first spine surgery using a multi-arm, navigation-based robotic system, marking a significant milestone in surgical robotics. - Zimmer Biomet announced a definitive agreement to acquire Monogram Technologies, signaling continued consolidation in the orthopedic robotics market.
- Zimmer Biomet received FDA 510(k) clearance for ROSA Knee with OptimiZe, an enhanced robotic-assisted knee replacement surgery system featuring personalized surgical planning capabilities. - The upgraded system reduces planning time by an average of 46% through proprietary OptimiZe Planning algorithm that creates customized surgical profiles based on surgeon preferences. - ROSA Knee with OptimiZe includes five key enhancements including improved landmarking, tracking, and automated kinematic alignment features designed to reduce user variability and improve surgical precision. - The system is designed for use with Zimmer Biomet's Persona Knee System and will undergo targeted release in late 2025 with commercial availability expected in Q1 2026.
- Johnson & Johnson announced plans to spin off its orthopedics business into a standalone company called DePuy Synthes within 18-24 months, generating $9.2 billion in fiscal year 2024 sales. - The separation aims to refocus J&J's medtech portfolio on higher-growth markets including cardiovascular and robotic surgery while creating what CEO Joaquin Duato claims will be the largest orthopedics company in the medical device space. - Former Smith & Nephew CEO Namal Nawana will lead the new orthopedics company, which competes in lower-growth markets compared to J&J's other medtech segments. - Following the spinout, J&J's medtech division will concentrate on cardiovascular, surgery, and vision businesses, continuing the company's portfolio transformation strategy initiated with the 2021 Kenvue consumer health separation.
- Zimmer Biomet and its subsidiary Paragon 28 have commercially launched two new foot and ankle trauma products designed for complex fracture cases. - The Gorilla Pilon Fusion Plating System provides dual-column fixation for severe or malunited tibial pilon fractures using type II anodized plates and percutaneous guides. - The Phantom TTC Trauma Nail offers expanded lengths of 150mm, 300mm, and 350mm with enhanced fixation capabilities for demanding trauma cases including tibiotalocalcaneal fusion. - Both systems are now available for foot and ankle specialists across the United States to address complex trauma scenarios.
- Zimmer Biomet has completed its $177 million acquisition of Monogram Technologies, an AI-driven orthopedic robotics company, creating the broadest portfolio of orthopedic robotics and navigation technologies. - Monogram's CT-based, semi-autonomous, AI-navigated total knee arthroplasty robotic technology received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants by early 2027. - The acquisition positions Zimmer Biomet to become the first orthopedic company to offer a fully autonomous robotic solution, with Monogram beginning clinical studies for the fully autonomous version in July 2025. - The transaction includes contingent value rights entitling shareholders to receive up to $12.37 in additional cash if certain product development, regulatory and revenue milestones are achieved through 2030.
- Zimmer Biomet received Japan PMDA approval for the iTaperloc Complete and iG7 Hip System, marking the world's first approved orthopedic implants with iodine technology designed to inhibit bacterial adhesion and prevent biofilm formation. - The innovative system addresses periprosthetic joint infection (PJI), which occurs in 1-2% of primary total joint arthroplasty procedures and carries mortality rates approaching those of breast cancer at 11%. - The iodine technology applies a controlled-release iodine layer through advanced anodization and electrophoresis during manufacturing, utilizing iodine's biocompatible properties without causing antibiotic resistance. - This approval strengthens Zimmer Biomet's infection management portfolio and represents a significant advancement in orthopedic implant design for improving patient safety in joint replacement surgeries.
